Mogrify

The page explains cellular reprogramming and deriving clinically valuable cell types.

The MOGRIFY technology was developed as a systematic means of identifying the optimal combination of transcription factors required to achieve direct cellular reprogramming, converting any cell type into any other.

The epiMOGRIFY technology was developed as a systematic means of epigenetically identifying the optimal growth factors required to drive and maintain cell identity.

The page describes in vivo reprogramming therapies for regenerative medicine and unmet clinical needs.

Mogrify develops in vivo reprogramming therapies and cell therapies using cellular reprogramming.

EpiMOGRIFY is an extension of the Company’s proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells in chemically defined media.

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, was named ‘The One to Watch’ at the Cambridge Independent Science and Technology Awards 2019.

A direct cell conversion technology (MOGRIFY V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (MOGRIFY V2).

Mogrify is based at TusPark’s Cambridge Bio-Innovation Centre, occupying 12,000 sq. ft of lab and office space as its anchor tenant.

Mogrify seeks biotech professionals to develop in vivo reprogramming therapies for patients.

Mogrify only accepts unsolicited CVs directly from candidates, not through agencies.

Mogrify’s board includes members with commercial and scientific expertise.

Mogrify was founded by Julian Gough, Owen Rackham, and Jose Polo, bringing commercial and scientific expertise.

Mogrify has developed a suite of proprietary cellular reprogramming technologies, which allow the systematic conversion and maintenance of any cell type into any other, a unique opportunity to develop novel in vivo reprogramming therapies and transform cell therapy.

Mogrify offers proprietary direct cell conversion technology.

Mogrify develops in vivo reprogramming therapies for degenerative diseases.

Mogrify’s Cookies Policy explains cookie usage on its website.

Mogrify raises an additional $10 million in Series A funding, totaling $46 million. The biopharmaceutical company develops in vivo reprogramming therapies to treat patients. Proceeds will advance pre-clinical translation and optimize its therapy platform.

Oct 2023MogrifyNews article

Mogrify and Astellas Pharma are partnering to develop in vivo regenerative medicine treatments for sensorineural hearing loss (SNHL). The collaboration merges Mogrify’s reprogramming therapy expertise with Astellas’s regenerative medicine capabilities to explore novel therapeutic approaches. Both companies aim to advance research in restoring hearing function through direct tissue regeneration.

Jul 2022Inside Precision MedicineNews article

Mogrify and Astellas collaborate to research **in vivo regenerative medicine** for treating **sensorineural hearing loss**. The partnership focuses on Mogrify’s **in vivo reprogramming therapies**, aiming to develop novel solutions. Both companies specialize in regenerative medicine, with Astellas leading in the field. The agreement marks a step toward advancing therapeutic approaches for hearing restoration.

Jul 2022MogrifyNews article

Mogrify raises **$33 million in Series A funding** to advance its **ex vivo cell therapies** and **in vivo reprogramming therapies**, including immuno-oncology and ophthalmology programs. The biopharmaceutical company uses the capital to expand its platform development and clinical applications. The funding round includes a second closing of **$17 million**, bringing the total to **$33 million**.

May 2021MogrifyNews article